Ets-1 regulates its target genes mainly by DNA methylation in human ovarian cancer

References

• Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genetics25:25–29.
   PubMed Web of Science ®Google Scholar
• Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C et al. 2007. NCBI GEO: mining tens of millions of expression profiles – database and tools update. Nucleic Acids Research 35(Database issue): D760–D765.
   Google Scholar
• Behrens P, Rothe M, Florin A, Wellmann A, Wernert N. 2001. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. International Journal of Molecular Medicine8:149–154.
   PubMedGoogle Scholar
• Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J et al. 2009. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. British Journal of Cancer100:134–144.
   PubMed Web of Science ®Google Scholar
• Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. 2002. Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. Journal of Biological Chemistry277:20399–20408.
   PubMed Web of Science ®Google Scholar
• Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A et al. 2001a. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clinical Cancer Research7:551–557.
   PubMed Web of Science ®Google Scholar
• Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Trope CG et al. 2001b. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. American Journal of Surgical Pathology25:1493–1500.
   PubMedGoogle Scholar
• Dittmer J, Nordheim A. 1998. Ets transcription factors and human disease. Biochimica et Biophysica Acta1377: F1–11.
   PubMedGoogle Scholar
• Falcon S, Gentleman R. 2007. Using GOstats to test gene lists for GO term association. Bioinformatics23:257–258.
   PubMed Web of Science ®Google Scholar
• Fujimoto J, Aoki I, Toyoki H, Khatun S, Tamaya T. 2002. Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers. Annals of Oncology13:1598–1604.
   PubMed Web of Science ®Google Scholar
• Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani S. A. 2002. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. Journal of Biological Chemistry277:41571–41579.
   Google Scholar
• Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N. 2008. The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Reviews in Medicinal Chemistry8:1095–1105.
   PubMed Web of Science ®Google Scholar
• Holschneider CH, Berek J. S. 2000. Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars in Surgical Oncology19:3–10.
   PubMed Web of Science ®Google Scholar
• Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC, Fasih N. 2011. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics31:625–646.
   PubMedGoogle Scholar
• Langmead B, Trapnell C, Pop M, Salzberg S. L. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biology10: R25.
   PubMed Web of Science ®Google Scholar
• Lefter LP, Dima S, Sunamura M, Furukawa T, Sato Y, Abe M et al. 2009. Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer. Cancer Gene Therapy16:137–148.
   PubMedGoogle Scholar
• Maglott D, Ostell J, Pruitt KD, Tatusova T. 2007. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Research35(Database issue): D26–D31.
   Google Scholar
• Oda N, Abe M, Sato Y. 1999. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. Journal of Cellular Physiology 178:121–132.
   PubMed Web of Science ®Google Scholar
• Okuducu AF, Zils U, Michaelis SA, Michaelides S, von Deimling A. 2006. Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology48:836–845.
   PubMedGoogle Scholar
• Park YH, Jung HH, Ahn JS, Im Y. H. 2008. Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochemical and Biophysical Research Communications377:389–394.
   PubMedGoogle Scholar
• Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S et al. 2002. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene21:2309–2319.
   PubMed Web of Science ®Google Scholar
• Sharrocks AD, Brown AL, Ling Y, Yates P. R. 1997. The ETS-domain transcription factor family. International Journal of Biochemistry and Cell Biology29:1371–1387.
   PubMedGoogle Scholar
• Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV et al. 2002. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene21:8506–8509.
   PubMedGoogle Scholar
• Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. 2002. c-Ets1 is a promising marker in epithelial ovarian cancer. International Journal of Molecular Medicine9:287–292.
   PubMedGoogle Scholar
• Tomita N, Morishita R, Taniyama Y, Koike H, Aoki M, Shimizu H et al. 2003. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, Ets-1. Circulation107:1411–1417.
   PubMed Web of Science ®Google Scholar
• Vandenbunder B, Queva C, Desbiens X, Wernert N, Stehelin D. 1994. Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development. Invasion and Metastasis14:198–209.
   PubMedGoogle Scholar
• Verschoor ML, Wilson LA, Verschoor CP, Singh G. 2010. Ets-1 regulates energy metabolism in cancer cells. PLoS ONE5: e13565.
   PubMed Web of Science ®Google Scholar
• Wasylyk B, Hagman J, Gutierrez-Hartmann A. 1998. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends in Biochemical Sciences23:213–216.
   PubMed Web of Science ®Google Scholar
• Wilson LA, Yamamoto H, Singh G. 2004. Role of the transcription factor Ets-1 in cisplatin resistance. Molecular Cancer Therapeutics3: 823–832.
   PubMedGoogle Scholar
• Yu W, Jin C, Lou X, Han X, Li L, He Y et al. 2011. Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS ONE6:e29450.
   PubMed Web of Science ®Google Scholar